FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W90219691> ?p ?o ?g. }

• W90219691 endingPage "2470" @default.
• W90219691 startingPage "2465" @default.
• W90219691 abstract "Abstract A high complete remission rate is currently achieved in patients with acute myeloid leukemia (AML). However, many patients eventually relapse due to the persistence of low numbers of residual leukemic cells that are undetectable by conventional cytomorphologic criteria (minimal residual disease [MRD]). Using immunophenotypic multiparametric flow cytometry, we have investigated in sequential studies (diagnosis and follow-up) the impact of MRD detection on the outcome of 53 AML patients that had achieved morphologic remission with standard AML protocols and displayed at diagnosis an aberrant phenotype. Patients were studied at diagnosis with a panel of 35 monoclonal antibodies in triple staining combinations for detection of aberrant or uncommon phenotypic features. According to these features, a patient's probe was custom-built at diagnosis for the identification of possible residual leukemic cells during follow-up. The level of MRD at the end of induction and intensification therapy correlated with the number of relapses and relapse-free survival (RFS). Thus, patients with more than 5 × 10−3 residual cells (5 residual cells among 1,000 normal bone marrow [BM] cells) identified as leukemic by immunophenotyping in the first remission BM showed a significant higher rate of relapse (67% v 20% for patients with less than 5 × 10−3 residual cells; P = .002) and a lower median RFS (17 months v not reached; P = .01). At the end of intensification, with a cut-off value of 2 × 10−3 leukemic cells, AML patients also separated into two distinct groups with relapse rates of 69% versus 32% (P = .02), respectively, and median RFS of 16 months versus not reached (P = .04). In addition, overall survival was also significantly related to the level of residual cells in the marrow obtained at the end of induction and particularly after intensification therapy (P = .008). Furthermore, we have explored whether residual disease was related with the functional expression of multidrug resistance (MDR-1) at diagnosis as assessed by the rhodamine-123 assay. Patients with ≥5 × 10−3 residual leukemic cells at the end of induction therapy had a significantly higher rhodamine-123 efflux (mean, 56% ± 24%) than those with less than 5 × 10−3 residual cells (mean, 32% ± 31%; P = .04). Finally, multivariate analysis showed that the number of residual cells at the end of induction or intensification therapy was the most important prognostic factor for prediction of RFS. Overall, our results show that immunophenotypical investigation of MRD strongly predicts outcome in patients with AML and that the number of residual leukemic cells correlates with multidrug resistance." @default.
• W90219691 created "2016-06-24" @default.
• W90219691 creator A5007471850 @default.
• W90219691 creator A5018662284 @default.
• W90219691 creator A5020989412 @default.
• W90219691 creator A5028122651 @default.
• W90219691 creator A5031467969 @default.
• W90219691 creator A5047978597 @default.
• W90219691 creator A5049441811 @default.
• W90219691 creator A5055139947 @default.
• W90219691 creator A5061223719 @default.
• W90219691 creator A5066182585 @default.
• W90219691 creator A5072328797 @default.
• W90219691 creator A5076916055 @default.
• W90219691 creator A5088409474 @default.
• W90219691 date "1997-09-15" @default.
• W90219691 modified "2023-10-15" @default.
• W90219691 title "Immunophenotyping Investigation of Minimal Residual Disease Is a Useful Approach for Predicting Relapse in Acute Myeloid Leukemia Patients" @default.
• W90219691 cites W1489279917 @default.
• W90219691 cites W1919339218 @default.
• W90219691 cites W2018250102 @default.
• W90219691 cites W2018489989 @default.
• W90219691 cites W2062121387 @default.
• W90219691 cites W2062912439 @default.
• W90219691 cites W2076035400 @default.
• W90219691 cites W2134362985 @default.
• W90219691 cites W2153400118 @default.
• W90219691 cites W2290043227 @default.
• W90219691 cites W2322652491 @default.
• W90219691 cites W4234192722 @default.
• W90219691 cites W4254545025 @default.
• W90219691 cites W990603645 @default.
• W90219691 doi "https://doi.org/10.1182/blood.v90.6.2465" @default.
• W90219691 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9310499" @default.
• W90219691 hasPublicationYear "1997" @default.
• W90219691 type Work @default.
• W90219691 sameAs 90219691 @default.
• W90219691 citedByCount "245" @default.
• W90219691 countsByYear W902196912012 @default.
• W90219691 countsByYear W902196912013 @default.
• W90219691 countsByYear W902196912014 @default.
• W90219691 countsByYear W902196912015 @default.
• W90219691 countsByYear W902196912016 @default.
• W90219691 countsByYear W902196912017 @default.
• W90219691 countsByYear W902196912018 @default.
• W90219691 countsByYear W902196912019 @default.
• W90219691 countsByYear W902196912020 @default.
• W90219691 countsByYear W902196912021 @default.
• W90219691 countsByYear W902196912022 @default.
• W90219691 crossrefType "journal-article" @default.
• W90219691 hasAuthorship W90219691A5007471850 @default.
• W90219691 hasAuthorship W90219691A5018662284 @default.
• W90219691 hasAuthorship W90219691A5020989412 @default.
• W90219691 hasAuthorship W90219691A5028122651 @default.
• W90219691 hasAuthorship W90219691A5031467969 @default.
• W90219691 hasAuthorship W90219691A5047978597 @default.
• W90219691 hasAuthorship W90219691A5049441811 @default.
• W90219691 hasAuthorship W90219691A5055139947 @default.
• W90219691 hasAuthorship W90219691A5061223719 @default.
• W90219691 hasAuthorship W90219691A5066182585 @default.
• W90219691 hasAuthorship W90219691A5072328797 @default.
• W90219691 hasAuthorship W90219691A5076916055 @default.
• W90219691 hasAuthorship W90219691A5088409474 @default.
• W90219691 hasBestOaLocation W902196911 @default.
• W90219691 hasConcept C126322002 @default.
• W90219691 hasConcept C142724271 @default.
• W90219691 hasConcept C143998085 @default.
• W90219691 hasConcept C196166836 @default.
• W90219691 hasConcept C203014093 @default.
• W90219691 hasConcept C2776694085 @default.
• W90219691 hasConcept C2778461978 @default.
• W90219691 hasConcept C2778729363 @default.
• W90219691 hasConcept C2779282312 @default.
• W90219691 hasConcept C2779823535 @default.
• W90219691 hasConcept C2780007613 @default.
• W90219691 hasConcept C3018657049 @default.
• W90219691 hasConcept C553184892 @default.
• W90219691 hasConcept C71924100 @default.
• W90219691 hasConcept C90924648 @default.
• W90219691 hasConceptScore W90219691C126322002 @default.
• W90219691 hasConceptScore W90219691C142724271 @default.
• W90219691 hasConceptScore W90219691C143998085 @default.
• W90219691 hasConceptScore W90219691C196166836 @default.
• W90219691 hasConceptScore W90219691C203014093 @default.
• W90219691 hasConceptScore W90219691C2776694085 @default.
• W90219691 hasConceptScore W90219691C2778461978 @default.
• W90219691 hasConceptScore W90219691C2778729363 @default.
• W90219691 hasConceptScore W90219691C2779282312 @default.
• W90219691 hasConceptScore W90219691C2779823535 @default.
• W90219691 hasConceptScore W90219691C2780007613 @default.
• W90219691 hasConceptScore W90219691C3018657049 @default.
• W90219691 hasConceptScore W90219691C553184892 @default.
• W90219691 hasConceptScore W90219691C71924100 @default.
• W90219691 hasConceptScore W90219691C90924648 @default.
• W90219691 hasIssue "6" @default.
• W90219691 hasLocation W902196911 @default.
• W90219691 hasOpenAccess W90219691 @default.
• W90219691 hasPrimaryLocation W902196911 @default.

• next